Back to top
more

Nevro (NVRO)

(Delayed Data from NYSE)

$4.92 USD

4.92
240,529

+0.09 (1.86%)

Updated Oct 14, 2024 04:00 PM ET

After-Market: $4.90 -0.02 (-0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Nevro (NVRO) Down 6.3% Since Last Earnings Report?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investors' confidence is high in Nevro (NVRO) stock, courtesy of its solid prospects.

Nevro (NVRO) Stock Slips 2.9% Despite Narrower Loss in Q1

by Zacks Equity Research

Nevro's (NVRO) international revenues rise on a year-over-year basis in Q1.

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 1.16% and 4.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Nevro (NVRO) Down 16% Since Last Earnings Report?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro (NVRO) Q4 Loss Narrower Than Estimated, Revenues Miss

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.

Nevro (NVRO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Posts Weak Preliminary Q4 and 2020 Revenues

by Zacks Equity Research

Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.

Nevro's (NVRO) FDA Submission to Treat Patients With PDN

by Zacks Equity Research

Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.

Why Is Nevro (NVRO) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 50.85% and 4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.

Nevro Bolsters Growth Prospects With New Manufacturing Plan

by Zacks Equity Research

Nevro (NVRO) commences plan for manufacturing operations in Costa Rica, thereby expanding its geographic footprint and boosting growth prospects.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Nevro (NVRO) continues to gain traction from Senza, its flagship platform, and R&D capabilities. However, stiff competition remains a woe.

Nevro (NVRO) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

Nevro (NVRO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 26.67% and 36.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ABIOMED (ABMD) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.

DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect weak segmental performance.

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Medical segment.

What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal third-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.